Technical Analysis for CATB - Catabasis Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
CATB closed up 1.2 percent on Friday, September 21, 2018, on 1.16 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
|Weak or Absent||Down||Up||Up|
|See historical CATB trend table...|
|Date||Alert Name||Type||% Chg|
|Sep 21||180 Bullish Setup||Bullish Swing Setup||0.00%|
|Sep 21||Stochastic Reached Overbought||Strength||0.00%|
|Sep 21||Overbought Stochastic||Strength||0.00%|
|Sep 21||Up 3 Days in a Row||Strength||0.00%|
|Sep 21||Up 4 Days in a Row||Strength||0.00%|
|Sep 20||Shooting Star Candlestick||Bearish||1.20%|
|Sep 20||Lizard Bearish||Bearish Day Trade Setup||1.20%|
|Sep 20||Pocket Pivot||Bullish Swing Setup||1.20%|
|Sep 20||Doji - Bearish?||Reversal||1.20%|
|Sep 20||Up 3 Days in a Row||Strength||1.20%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Catabasis Pharmaceuticals, Inc. (Catabasis) is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics based on its safely metabolized and rationally targeted (SMART) linker technology platform. Its SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating various biological targets in one or more related disease pathways. Catabasis engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of its SMART linkers. Catabasis is also engaged in developing other product candidates for the treatment of lipid disorders. The Company's product development pipeline includes three clinical-stage product candidates, namely, CAT-1004, CAT-2000 series, including CAT-2054 and CAT-2003, and CAT-4001, and various programs in preclinical development.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more CATB news...
|52 Week High||3.78|
|52 Week Low||0.61|
|200-Day Moving Average||1.3558|
|50-Day Moving Average||0.7206|
|20-Day Moving Average||0.7641|
|10-Day Moving Average||0.791|
|Average True Range||0.0615|
|Chandelier Exit (Long, 3 ATRs )||0.6755|
|Chandelier Exit (Short, 3 ATRs )||0.8245|
|Upper Bollinger Band||0.8468|
|Lower Bollinger Band||0.6814|
|Percent B (%b)||0.96|
|MACD Signal Line||0.0134|
|Market Cap||18.88 Million|
|Num Shares||22.5 Million|
|Price-to-Earnings (P/E) Ratio||-0.49|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||0.92|
|Resistance 3 (R3)||0.91||0.87||0.90|
|Resistance 2 (R2)||0.87||0.85||0.88||0.90|
|Resistance 1 (R1)||0.86||0.84||0.87||0.87||0.89|
|Support 1 (S1)||0.81||0.80||0.82||0.82||0.79|
|Support 2 (S2)||0.77||0.79||0.78||0.78|
|Support 3 (S3)||0.76||0.77||0.78|
|Support 4 (S4)||0.77|